Single-arm Clinical Trial of TACE in Combination With Icaritin as Adjuvant Therapy After Surgery in Patients With Hepatocellular Carcinoma at High Risk of Recurrence

This study is testing whether adding icaritin (an herbal-derived compound) after TACE (a liver-directed procedure that delivers chemotherapy directly to liver tumors) helps prevent liver cancer from coming back in patients who have had surgery to remove their tumor but are at high risk of recurrence. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with hepatocellular carcinoma (liver cancer) confirmed by biopsy - You had a complete surgical removal of your tumor (R0 resection) 4–8 weeks ago - You have high-risk features for recurrence, such as a large tumor (≥5 cm), multiple tumors, blood vessel invasion, or low-grade differentiation - You have good liver function (Child-Pugh score 5–6) and good performance status **You may NOT be eligible if...** - Your tumor is a rare subtype (sarcomatoid, fibrolamellar, or mixed liver-bile duct cancer) - You have had another cancer in the past 5 years - You have significant heart, brain, lung, or kidney problems - There is evidence that your cancer has already come back before enrollment - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.